Table 3.

Comparing rates of TE in patients with SCD on different types of CHC and POC formulation

Type of contraceptiveRates of TE per 1000 person-y (95% CI)Unadjusted HR (95% CI)PAdjusted∗ HR (95% CI)P
Contraception group      
CHC 17.2 (12.9-23.1) 0.70 (0.48-1.00) .051 0.83 (0.58-1.21) .336 
POC 24.7 (19.9-30.7) Reference — Reference — 
CHC formulation      
OCP†  15.2 (10.8-21.4) Reference — Reference — 
Transdermal patch 33.7 (16.8-67.3) 2.21 (1.02-4.78) .044 2.39 (1.09-5.24) .031 
Vaginal ring 19.5 (7.3-51.9) 1.27 (0.45-3.57) .657 1.23 (0.43-3.51) .694 
POC formulation      
IUD 42.0 (28.1-62.6) Reference — Reference — 
POP 11.4 (4.3-30.4) 0.27 (0.09-0.78) .016 0.38 (0.13-1.11) .078 
DMPA 21.5 (16.0-28.9) 0.51 (0.31-0.84) .008 0.67 (0.40-1.11) .117 
Implant 29.2 (15.2-56.2) 0.70 (0.32-1.50) .355 1.00 (0.46-2.17) .996 
Type of contraceptiveRates of TE per 1000 person-y (95% CI)Unadjusted HR (95% CI)PAdjusted∗ HR (95% CI)P
Contraception group      
CHC 17.2 (12.9-23.1) 0.70 (0.48-1.00) .051 0.83 (0.58-1.21) .336 
POC 24.7 (19.9-30.7) Reference — Reference — 
CHC formulation      
OCP†  15.2 (10.8-21.4) Reference — Reference — 
Transdermal patch 33.7 (16.8-67.3) 2.21 (1.02-4.78) .044 2.39 (1.09-5.24) .031 
Vaginal ring 19.5 (7.3-51.9) 1.27 (0.45-3.57) .657 1.23 (0.43-3.51) .694 
POC formulation      
IUD 42.0 (28.1-62.6) Reference — Reference — 
POP 11.4 (4.3-30.4) 0.27 (0.09-0.78) .016 0.38 (0.13-1.11) .078 
DMPA 21.5 (16.0-28.9) 0.51 (0.31-0.84) .008 0.67 (0.40-1.11) .117 
Implant 29.2 (15.2-56.2) 0.70 (0.32-1.50) .355 1.00 (0.46-2.17) .996 
∗

Adjusted for age group, SCD genotype, SCD severity, and comorbidities of obesity, smoking, diabetes, hypertension, hyperlipidemia, and cancer.

†

Patients receiving high-dose estrogen OCP (n < 10) were excluded from this analysis.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal